7Baggers

Novo Nordisk
(NYSE:NVO) 

NVO stock logo

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1...

Founded: 1923
Full Time Employees: 44,326
Founder: August Krogh, H.C. Hagedorn, August Kongsted 
CEO: Maziar Mike Doustdar  
Sector: Healthcare
Industry: Biotechnology
Healthcare
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
  • Strong Demand for GLP-1 Therapies Drives Growth: Novo Nordisk continues to benefit from robust global demand for its GLP-1 portfolio, supporting strong sales momentum and market share gains in obesity and diabetes.
  • Capacity Expansion and Supply Constraints in Focus: Manufacturing scale-up and supply availability remain key execution priorities as the company invests to expand fill-finish and production capacity to meet sustained demand.
  • Pipeline and Indication Expansion Provide Longer-Term Upside: Ongoing clinical development and label expansions across obesity, cardiometabolic disease, and related comorbidities could extend the growth runway beyond current flagship products.
  • Competitive Intensity Rising in the Obesity Market: Competition from other incretin-based therapies and next-generation entrants is increasing, making differentiation on efficacy, safety, supply reliability, and pricing more important.
  • Pricing and Reimbursement Scrutiny Remains a Key Risk: As GLP-1 adoption expands, payer management, government pricing policies, and reimbursement dynamics could influence net pricing, access, and long-term profitability.
Bull Thesis:
  • Dominance in GLP-1 Market with Ozempic/Wegovy: Novo Nordisk holds a leading position in the rapidly expanding GLP-1 market for diabetes and obesity with blockbusters like Ozempic (semaglutide for diabetes) and Wegovy (semaglutide for obesity). Demand continues to outstrip supply, indicating massive unmet need and strong pricing power.
  • Robust Pipeline and Expanding Indications: Beyond current indications, Novo Nordisk is exploring GLP-1s for new areas like cardiovascular benefits (SELECT trial success for Wegovy), kidney disease, and NASH, potentially opening up even larger addressable markets and extending patent life. Oral semaglutide (Rybelsus) also offers convenience and market differentiation.
  • Significant Manufacturing Capacity Expansion: Novo Nordisk is investing heavily in expanding its manufacturing capacity for GLP-1s, which will allow it to meet surging global demand, capture market share, and maintain its competitive edge over rivals struggling with production ramp-up.
  • Strong Financial Performance and Profitability: The high demand and premium pricing for its GLP-1 drugs translate into excellent revenue growth, high-profit margins, and strong free cash flow generation, supporting further R&D, strategic acquisitions, and attractive shareholder returns.
Bear Thesis:
  • Increasing Competition from Eli Lilly and Others: Eli Lilly's Mounjaro (tirzepatide) and Zepbound (tirzepatide for obesity) are showing strong efficacy, and other competitors are entering the GLP-1 and dual-agonist space, potentially eroding Novo Nordisk's market share and pricing power over time.
  • Potential for Pricing Pressure and Reimbursement Hurdles: As more GLP-1 drugs become available and healthcare systems face budget constraints, there could be increasing pressure on pricing, especially for obesity indications where reimbursement is still evolving and often limited, impacting profitability.
  • Persistent Supply Chain Constraints Limiting Growth: Despite expansion efforts, Novo Nordisk has struggled to consistently meet the overwhelming demand for Wegovy and Ozempic, leading to rationing, lost sales opportunities, and potential frustration among patients and prescribers, which could push some to competitor products.
  • Over-reliance on a Single Drug Class (GLP-1s): A significant portion of Novo Nordisk's revenue and future growth is tied to the continued success of its GLP-1 franchise. Any major setback (e.g., new competition, unexpected safety issues, regulatory changes, or a shift in treatment paradigms) could have a disproportionately large negative impact on the company.
Main Competitors:
  • Eli Lilly and Company ($LLY) (Mounjaro (tirzepatide), Zepbound (tirzepatide), Trulicity (dulaglutide), Jardiance (empagliflozin)), Eli Lilly is Novo Nordisk's most direct and formidable competitor, particularly in the rapidly growing diabetes and obesity markets. Their dual GIP/GLP-1 agonist, tirzepatide (Mounjaro for diabetes, Zepbound for obesity), directly challenges Novo Nordisk's GLP-1 blockbusters like Ozempic and Wegovy, often demonstrating superior weight loss and glycemic control in clinical trials. They also compete with other diabetes medications like Trulicity and Jardiance.
  • Sanofi S.A. ($SNY) (Lantus (insulin glargine), Toujeo (insulin glargine), Soliqua/Suliqua (insulin glargine/lixisenatide), rare disease therapies), Sanofi has historically been a major competitor in the global insulin market with products like Lantus and Toujeo, directly competing with Novo Nordisk's insulin portfolio. While they have struggled to gain significant traction in the GLP-1 space, they remain a broad pharmaceutical company with a presence in diabetes care and various rare disease segments, including hemophilia, where they indirectly compete with Novo Nordisk's rare disease offerings.
  • AstraZeneca PLC ($AZN) (Farxiga/Forxiga (dapagliflozin), broader cardiovascular-renal-metabolic portfolio), AstraZeneca competes in the broader diabetes market, primarily with its SGLT2 inhibitor Farxiga (Forxiga), which has demonstrated significant cardiovascular and renal benefits beyond glycemic control. While their GLP-1 presence (exenatide) has diminished, Farxiga directly competes for market share in diabetes management, often used in combination or as an alternative to GLP-1s, and they have a strong pipeline in related metabolic and cardiovascular diseases.
  • Takeda Pharmaceutical Company Limited ($TAK) (Adynovate (antihemophilic factor), Vonvendi (von Willebrand factor), various rare disease therapies), Takeda is a significant global player in rare diseases, including hemophilia, which is one of Novo Nordisk's key therapeutic areas outside of diabetes and obesity. Takeda's hemophilia treatments, such as Adynovate, compete for market share and patient access with Novo Nordisk's hemophilia portfolio, requiring continuous innovation and patient support programs.
Moat:
Novo Nordisk's competitive moat is built on its deep expertise and long-standing leadership in diabetes care, particularly its innovative GLP-1 receptor agonist portfolio (Ozempic, Wegovy, Rybelsus). This is supported by robust R&D, strong patent protection, established brand recognition, and extensive manufacturing capabilities for complex biologics. However, the competitive landscape is exceptionally fierce, especially in the rapidly expanding obesity and diabetes markets. Key rivals like Eli Lilly are introducing highly effective next-generation therapies (e.g., tirzepatide), while other major pharmaceutical companies are actively developing novel treatments and oral formulations. Competition also extends to rare diseases and broader metabolic health, requiring continuous innovation, strategic pricing, and strong market access to maintain its leadership position.
Income Statements:
Quarterly
Annual
    Unit: USD 
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2018-09-30 2018-02-01 2017-11-01 2017-05-03 2016-04-29 2015-10-29 2015-08-06 2015-04-30 2015-01-30 2014-10-30 
                
        assets
      		          
        intangible assets
      		4,610 3,325 2,615 2,771 2,157 1,465 1,460 1,372 1,378 1,398 
        property, plant and equipment
      		39,555 35,247 33,128 31,096 25,863 23,977 23,632 23,464 23,136 22,612 
        investment in associated company
      		528 784 780 785 796 806 802 798   
        deferred income tax assets
      		2,051 1,941 2,841 2,658 6,009 6,185 6,661 7,317 5,399 5,277 
        other financial assets
      		1,016 978 1,433 1,255 1,162 1,274 1,421 1,045 856 825 
        total non-current assets
      		47,760 42,275 40,797 38,565 35,987 33,707 33,976 33,996 30,769 30,112 
        inventories
      		15,922 15,373 15,230 15,044 12,995 12,762 12,825 12,288 11,357 11,285 
        trade receivables
      		18,534 20,165 17,199 17,012 16,502 13,565 14,209 14,648 13,041 10,813 
        tax receivables
      		309 958 322 2,656 3,990 4,240 5,063 6,623 3,210 2,449 
        other receivables and prepayments
      		2,725 2,428 2,632 2,868 2,627 2,826 3,022 2,460 2,750 2,996 
        derivative financial instruments
      		244 2,304 2,574 302 1,417 587 379 254 30 8 
        cash at bank
      		16,401 18,852 19,134 16,763       
        total current assets
      		54,135 60,080 57,094 55,648 46,381 51,488 47,337 43,461 46,293 41,171 
        total assets
      		101,895 102,355 97,891 94,213 82,368 85,195 81,313 77,457 77,062 71,283 
        equity and liabilities
      		          
        share capital
      		490 500 500 510 520 520 520 530 530 530 
        treasury shares
      		 -11  -13    -13 -11  
        retained earnings
      		49,007 48,977 45,262 40,739 36,070 42,797 39,353 34,790 41,277 38,743 
        other reserves
      		 349 1,192 -935 706  -756 -3,199 -1,502  
        total equity
      		47,512 49,815 46,946 40,301 37,284 43,109 39,111 32,108 40,294 37,967 
        deferred income tax liabilities
      		362 846 1,358 13 13 11 19 42 7 9 
        retirement benefit obligations
      		1,256 1,336 1,331 1,382 1,281 1,160 1,199 1,280 1,031 984 
        provisions
      		3,340 3,302 3,129 3,614 2,716 2,392 2,391 2,038 2,041 2,292 
        total non-current liabilities
      		4,958 5,484 5,818 5,009 4,010 3,563 3,609 3,360 3,079 3,285 
        current debt
      		337 1,694 260 613 406 630 736 594 720 284 
        trade payables
      		4,846 5,610 4,530 3,782 3,740 3,845 3,932 4,014 4,950 2,988 
        tax payables
      		4,426 4,242 5,565 4,354 4,861 3,313 3,234 3,232 2,771 3,166 
        other liabilities
      		13,252 14,446 13,660 16,295 15,092 12,418 12,249 14,051 11,051 10,564 
        total current liabilities
      		49,425 47,056 45,127 48,903 41,074 38,523 38,593 41,989 33,689 30,031 
        total liabilities
      		54,383 52,540 50,945 53,912 45,084 42,086 42,202 45,349 36,768 33,316 
        total equity and liabilities
      		101,895 102,355 97,891 94,213 82,368 85,195 81,313 77,457 77,062 71,283 
        marketable securities
      		  3 1,003 4,032 2,024 3 1,204 1,509 1,516 
        cash at bank and on hand
      		    4,818 15,484 11,836 5,984 14,396 12,104 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2017-11-01 2017-08-09 2017-05-03 2017-02-02 2016-10-28 2016-08-05 2016-04-29 2016-02-03 2015-10-29 2015-08-06 2015-04-30 2015-01-30 2014-10-30 2014-08-07 2014-05-01 
                       
          dkk million
        		               
          +
        		               
          =
        		               
          net profit
        		29,877 20,107 10,156 37,925 29,226 19,423 9,455  26,602 18,219 9,876  19,952 13,452 6,458 
          adjustment for non-cash items:
        		               
          income taxes in the income statement
        		8,232 5,540 2,848 9,873 7,630 5,132 2,498 8,623        
          depreciation, amortisation and impairment losses
        		2,277 1,571 708 3,193 2,077 1,341 624 2,959 1,944 1,311 663 3,435    
          other non-cash items
        		1,828 1,463 1,995 3,882 1,423 214 1 5,908 5,312 4,173 2,319 4,163    
          change in working capital
        		  -90       -3,041  -2,148  -2,990  
          interest received
        		90 69 30 114 110 96 14 55 59 61 22 131 119 110 56 
          interest paid
        		  -21       -26  -78  -14  
          income taxes paid
        		  -3,528  257     -6,905  -7,907  -4,245  
          net cash generated from operating activities
        		35,136 22,215 12,098 48,314 37,161 21,972 7,475 38,287 28,168 16,080 4,106 31,692 24,391 12,194 4,069 
          purchase of intangible assets
        		  -108             
          proceeds from sale of property, plant and equipment
        		6 6  7 2 1  15 6 6 3 4 2 18 4 
          purchase of property, plant and equipment
        		  -1,604       -1,788  -3,990  -1,513  
          proceeds from other financial assets
        		11 11  23 16 1  32        
          purchase of other financial assets
        		               
          sale of marketable securities
        		2,006 2,006 1,006 2,064 2,029 2,019  1,500 1,506 1,506 305 2,232    
          purchase of marketable securities
        		               
          dividend received from associated company
        		26 14 14 26 26 25          
          net cash from investing activities
        		  -692         -2,064  547 416 
          purchase of treasury shares
        		  -4,245       -7,759  -14,667  -6,841  
          dividends paid
        		  -11,448       -12,905  -11,866  -11,866  
          net cash from financing activities
        		  -13,725       -20,664  -26,533  -18,707  
          net cash generated from activities
        		641 1,345 -2,319 2,637    2,088 1,111 -2,685  3,095 1,243 -5,966  
          cash and cash equivalents at the beginning of the year
        		18,461 18,461 18,461 15,850 15,850 15,850 15,850 13,676  13,676 13,676 10,513   10,513 
          exchange gain on cash and cash equivalents
        		  8     86 67 109 130  64 48 14 
          cash and cash equivalents at the end of the period
        		18,873 19,644 16,150 18,461 14,081 12,761 4,412  14,854 11,100 5,390  11,820 4,595 1,836 
          withheld dividend tax
        		  1,968    2,811    2,340    2,102 
          nnit non-recurring income included in 'other operating income'
        		               
          proceeds from the partial divestment of nnit a/s
        		       2,303        
          dividend recieved from associated company
        		      25         
          net profit for the year
        		       34,860    26,481    
          cash and cash equivalents at the end of the year
        		       15,850    13,676    
          income taxes
        		        6,567 4,814 2,609 7,615    
          nnit non-recurring income included in 'other operating income' 1)
        		         -2,526      
          proceeds from the partial divestment of nnit a/s 2)
        		        2,303 2,303 2,303     
          proceeds from sale of other financial assets
        		        32 28 28     
          purchase of intangible assets and other financial assets
        		         -156  -345 289 -177  
          net cash generated from investing activities
        		         1,899 1,842     
          cash and cash equivalents at the beginning of the yea
        		        13,676       
          proceeds from intangible assets and other financial assets
        		           35 58   
          exchange gains on cash and cash equivalents
        		           68    
          adjustment for non-cash items
        		            11,363 5,881 2,023 
          net change in marketable securities
        		            2,225   
          cash and cash equivalents at the beginning of the period
        		            10,513 10,513  
          proceeds of other financial assets
        		               
          net disposed marketable securities
        		             2,219 1,213 
          free cash flow
        		               
          reconciliation of cash to earnings
        		               
          /